A review of perioperative statin therapy for noncardiac surgery

Sara Skrlin, Vivian Hou

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations


The leading cause of perioperative morbidity and mortality after major noncardiac surgery is cardiovascular complications. Clinical trials of lipid-lowering 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) have shown improved cardiovascular outcomes; therefore, statins have become a mainstay in the prevention of cardiovascular disease. Retrospective trials and a small number of prospective randomized trials indicate that statin use may be beneficial during the perioperative period. In addition to the effects on serum lipid levels, statins influence inflammatory, thrombotic, and vasodilatory cellular pathways; and thus, their beneficial effects are not limited to patients with hypercholesterolemia. This review will (1) examine the evidence for using perioperative statin therapy in the noncardiac surgical patient (2) explore the possible consequences of statin withdrawal, and (3) revisit the evidence for the safety of statin use. Further studies are still needed to establish the optimal dosage as well as timing and length of statin therapy perioperatively.

Original languageEnglish (US)
Pages (from-to)283-290
Number of pages8
JournalSeminars in Cardiothoracic and Vascular Anesthesia
Issue number4
StatePublished - Dec 2010


  • HMG-CoA reductase inhibitors
  • perioperative period
  • statins
  • surgery

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Anesthesiology and Pain Medicine


Dive into the research topics of 'A review of perioperative statin therapy for noncardiac surgery'. Together they form a unique fingerprint.

Cite this